Sabag Mark 4

What Happened Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries Ltd (TEVA), reported the sale of 62,102 ordinary shares (may be represented by ADSs) in open‑market transactions on March 17, 2026. The sales were recorded at a weighted average price of $30.14 per share (prices ranged $30.115–$30.215), for aggregate proceeds of about $1,871,816. This was a sale (S), which is typically considered routine cashing‑out rather than a bullish signal.

Key Details

• Transaction date: March 17, 2026; Form 4 filed March 19, 2026 (filed timely).
• Shares sold: 62,102; weighted average price: $30.14; total proceeds ≈ $1,871,816.
• Price range: $30.115 to $30.215 across multiple trades (reporting person will provide per‑trade breakdown on request).
• Footnote: Ordinary Shares may be represented by American Depositary Shares (each currently represents one Ordinary Share).
• Shares owned after transaction: not specified in the provided filing.
• Transaction code: S (sale). No 10b5‑1 plan, tax withholding, or late‑filing flag noted in the disclosed items.

Context Sales by executives can be routine (e.g., diversification or cash needs) and don’t necessarily indicate a change in company outlook. Retail investors often weigh insider purchases more heavily than sales; this disclosure documents the transaction but does not reveal the insider’s motivation.